Cost cuts are coming for Allergan, CEO Brent Saunders says

Discussion in 'Allergan' started by anonymous, Nov 3, 2017 at 5:42 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    My prediction is any people displaced will be realigned to the Restasis initiative. Restasis is BSs pet. He will increase voice level to squeeze every penny out of it. That is why he has been so successful. Just thoughts.
     
  2. anonymous

    anonymous Guest

    Do these layoffs pertain to the aesthetic division or just primary care reps? I am in the process of interviewing for BDM position...
     
  3. anonymous

    anonymous Guest

    Restasis is Brent's pet? This is laughable.

    He had nothing to do with formulation it, nothing to do with designing the clinical studies (no easy task I might add for a dry eye product), nothing to do with getting FDA approval (very difficult task for this first in class drug), etc. Nothing to do with writing the most recent 6 patents on it. Seriously, nothing to do with it at all in any regard.

    He may love the product. It is a top seller but he certainly shouldn't get credit for the success of Restasis. Restasis was successful due to the efforts of Allergan's former R&D team long before Brent was on the scene.
     
  4. anonymous

    anonymous Guest

    Welcome to 2017! And the reality that someone else with Big Words “BOLD” and fake euphoniums “Growth Pharma” stole your concepts and your company. The saddest thing to me is that they get away with it and are handsomely rewarded. Welcome to the middle class; Brent Saunders and the board at AGN hear you, NOT and care about your
    Contribution. Sweet Dreams
     
  5. anonymous

    anonymous Guest

    All. Facial has way too many BDM’s, managers and directors. Our APC’s aren’t worth anything. We should start there. Train the bdms to do the same benchmarking reports.
     
  6. anonymous

    anonymous Guest


    Some of what you say is probably true but BS had put a lot of resources and time into Restasis. You referenced it above with the new patents he spearheaded and the new delivery system. He loves the brand and will protect it at all cost by adding head count where it makes sense.
     
  7. anonymous

    anonymous Guest

    wake up! All of this postilating is seriously a waste of your time. As with everything in life, it’s all about the money! Shareholders will demand a dramatic response to the many billions lost at AGN. The tribal debacle was the holy grail of a desperate act. The timing of the disclosure? Well, that’s the leadership here; beyond bad.
    The Bell willToll and it won’t be BS who pays; That’s you, me and everybody else.
     
  8. TeaBagAnErin

    TeaBagAnErin Guest

    Pfizer dodged a bullet when the acquisition went south.

    Looks like the traditionalists were cotreat in their skepticism towards growth pharma. All the company's that bet their existence on research and development have started growing again.

    How much will the cash payout to the board be when they sell off GI, womans health and the Botox franchise?

    The conversation has to be about selling at this point as other molecules are years away from FDA submission.
     
  9. anonymous

    anonymous Guest



    There are two big phase 3's due out in 2018. Oral migraine phase 3 1st qtr to 1st half of year, Uterine Fibroid approval sometime in 2018 and AMD phase 3 data at 3rd qtr to end of 2018. You should really get your info straight instead of spouting off with your emotional instability. That's just 2018. 2019 should see the non-ketamine depression drug as well as many others. 6 top tier drugs the industry has suggested could bring in as much as 13 billion per year.
     
  10. anonymous

    anonymous Guest

     
  11. anonymous

    anonymous Guest

    What kind of drugs are you on? The stock price has gone from over $300 a share to $175 a share. The allergan and restasis name is all over the news for all the wrong reasons.

    The Restasis patents were in place before Pyott left. The MDPF bottle was in place before Pyott left, the clinical studies and stability studies just needed to finish to get approval.

    I have zero confidence in Brent's leadership.
     
  12. anonymous

    anonymous Guest

    Maybe the hospital division still has a chance then?
     
  13. anonymous

    anonymous Guest

    Wait Saunders was instrumental in the launch and development of the Multidose bottle. That is incorrect.
     
  14. anonymous

    anonymous Guest

    exactly that bottle was in development back in late 2013 long before acquisition, when the company was acquired development was about done on that delivery system
     
  15. anonymous

    anonymous Guest


    Yep...Saunders has built the Restasis brand and expanded its footprint in his short time with the product he has worked miracles. Far more than DP ever did and more committed to the business.